Novo Nordisk has launched Novoeight (antihemophilic factor [recombinant]) in the U.S. for people living with hemophilia A.
A new experimental drug could boost the immune system in older adults by as much as 20 percent, as well as help them to delay other aging effects.
The U.S. Food and Drug Administration(FDA) has finalized three guidance documents outlining its expectations for biosimilars.
Results from a human trial of GlaxoSmithKline’s Ebola vaccine show it is safe and generates an immune response.
The U.S. Department of Health and Human Services has launched a $133 million initiative to reduce prescription opioid and heroin-related overdose, death and dependence.
An international team of researchers has identified a gene that may be a missing link between overactive and underactive immune activity, and that may also play a key role in autoimmune diseases.
In response to the national measles outbreak, the American Academy of Pediatrics has released updated measles guidelines on its website.
Novo Nordisk has signed an agreement with Janssen Biotech Inc.
A recent study found no link between the measles vaccine and autism.
GlaxoSmithKline has developed a new shingles vaccine that is 97 percent effective in adults ages 50 years to 70 years.
A growing number of employers and insurers are limiting how much they’ll pay for certain medical services, according to a recent study.
ADMA Biologics has received positive results on the primary and secondary endpoint evaluations from the Phase III trial for its intravenous immune globulin (IVIG) product RI-002 to treat primary immunodeficiency disease(PI).